Skip to content
type1.science

Medtronic MiniMed 780G (pump)

Medtronic

What it is

Medtronic's flagship tubed pump: a durable, AA-battery-powered body holding up to 300 units that runs the SmartGuard advanced hybrid closed-loop algorithm (ranked separately). It pairs with the Guardian 4 and Simplera Sync sensors and, since 2025, Abbott's Instinct sensor, supports a 7-day Extended infusion set, and is waterproof — but bolusing is entered on the pump, with no phone-bolus option described. Available in the US, UK and EU, with product configurations region-specific. FDA lists several open corrections; affected scope depends on model, serial, software and region.

Editorial review: .

Most recent recorded citation date: 2026-09-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Available nowRegulator-approvedpumptubeddurable

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
Benefit or performance
Reliability: Long Medtronic pump lineage and a very large evidence base, but FDA lists several open corrections: a Class I impact/battery warning, a battery-cap issue, position-related over-/under-delivery, and version-specific software faults that can under-, over-, or stop delivery. Exact affected model/serial/version matters.[2]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 60 × 20 + 68 × 20 + 55 × 20 + 35 × 15 + 80 × 10 + 70 × 15 = 6035; divide by total weight 100. Unrounded weighted result: 60.35.

Interoperability60

Works with Medtronic's Guardian 4 and Simplera Sync sensors and, since the 2025 iAGC clearance, Abbott's Instinct sensor — but it is a closed system that does not support DIY/open-source loops.[8]

Reliability68

Long Medtronic pump lineage and a very large evidence base, but FDA lists several open corrections: a Class I impact/battery warning, a battery-cap issue, position-related over-/under-delivery, and version-specific software faults that can under-, over-, or stop delivery. Exact affected model/serial/version matters.[2]

Form factor55

A tubed, durable pump typically worn on a belt or in a pocket. Its IPX8 rating at manufacture is 3.6 m for 24 hours when the reservoir and tubing are correctly fitted, but MiniMed instructs users to remove it before swimming or bathing.[20]

Phone control35

The MiniMed Mobile app covers monitoring and sharing; all boluses are entered on the pump itself via the Bolus Wizard — MiniMed describes no phone-bolus option.[10]

Capacity80

Holds up to 300 units (3.0 mL) of U-100 insulin and pairs with a 7-day Extended infusion set — the longest reservoir-plus-set endurance in the class by our comparison.[11]

Access & cost70

Available in the US and Europe and recommended by NICE for NHS use under its hybrid closed-loop rollout; as durable hardware it involves a pump plus ongoing reservoir/infusion-set and sensor consumables.[18]

Editor’s take

The high-capacity, do-everything tubed workhorse. Its 300-unit reservoir, 7-day infusion set and aggressive SmartGuard algorithm are genuine strengths, and the Abbott Instinct deal finally breaks Medtronic's sensor lock-in. The glaring gap versus Tandem and Omnipod is the lack of phone bolusing — in 2026 you still reach for the pump to eat.

The full picture

The MiniMed 780G is Medtronic's flagship insulin pump and the durable, high-capacity counterpoint to tubeless patch pumps: a robust pump body connected by thin tubing to an infusion set, running the SmartGuard advanced hybrid closed-loop algorithm.7 On this site the SmartGuard algorithm is ranked separately as an AID system; this record covers the pump hardware itself.

Form factor: a tubed, durable pump. The reusable pump is typically worn on a belt clip or in a pocket, with tubing leading to a separately inserted infusion set.13 At manufacture, with reservoir and tubing correctly inserted, its IPX8 rating is 3.6 metres for up to 24 hours. MiniMed nevertheless instructs users to remove the pump before swimming or bathing; underwater CGM transmission may stop.20

Reservoir and wear. The reservoir holds up to 300 units (3.0 mL) of U-100 rapid-acting insulin — meaningfully more than the ~200-unit ceiling of typical patch pumps, which can suit people with higher insulin needs.1311 The infusion set is changed separately from the reservoir, and if you run low on insulin you can swap the reservoir without re-siting the cannula.13

Infusion set, cannula and 7-day wear. The 780G works with Medtronic's range of infusion sets, and uniquely supports the Extended infusion set — the first and only set cleared to be worn for up to 7 days, versus the 2–3 days of conventional sets.1112 Its new H-Cap tubing connector and materials are designed to improve insulin stability and reduce the risk of infusion-set occlusion over the longer wear, meaning fewer insertions.12

Occlusion detection and reliability. The pump is designed to monitor delivery for blockages and alarm on a detected occlusion.13 It rests on a large published evidence base: in the ADAPT randomized controlled trial, adults switched from injections to the 780G system lowered HbA1c by 1.54 percentage points (from 9.00% to 7.32%) versus near-no-change on injections, with no diabetic ketoacidosis according to the PubMed abstract.21 Those gains were sustained at 12 months.22

Which CGMs and algorithms it works with. The pump runs SmartGuard with Medtronic's own Guardian 4 and Simplera Sync sensors, and — following a September 2025 FDA clearance of the SmartGuard algorithm as an interoperable automated glycemic controller (iAGC) — with Abbott's Instinct sensor, a 15-day wear CGM built for Medtronic AID.8 It is a closed commercial system and does not work with DIY/open-source loops.13

Phone bolusing. This is the pump's clearest limitation: the MiniMed Mobile app covers monitoring and sharing, for seeing glucose and pump data and sharing it with followers. Every bolus is still entered on the pump itself using the on-board Bolus Wizard — MiniMed describes no phone-bolus option, unlike Omnipod 5 or Tandem's phone-bolus systems.10

Several FDA recalls/corrections are open. They do not all cover the same pumps. Class I Z-0003-2025 covers all serial numbers of listed 670G/770G/780G models worldwide: a drop, bump, or impact can damage internal components, shorten battery life and compress the warning time before insulin stops.2 Class II Z-1359-2022 covers specified outside-US 780G serials whose battery-cap contact can deteriorate and cut power; affected caps require inspection/replacement.3 Class II Z-1741-2026 is a broad position/labeling correction across MiniMed pumps, including all 780G models: a pump held too high relative to the infusion site can over-deliver, while one held lower can under-deliver; the updated instruction says never place it more than 14 inches (35.5 cm) above the site.6

Three version-specific Class II software corrections are also open: Z-1238-2026 for software 6.60 (Errors 41/43 can stop delivery), Z-1635-2026 for named 6.60/6.61 pumps and identified 6.62 defects (under-, over-, or no delivery), and Z-2698-2026 for 778 international pumps on 6.62 paired with Instinct (Errors 53 then 23 can stop delivery; update to 6.63).451 Exact model, serial, version, sensor pairing and region determine which correction applies; this is not a claim that every pump has every defect.

Access and cost by region. The 780G was FDA-approved in April 2023 for ages 7 and older with type 1 diabetes, and in 2025 gained a European CE Mark expanding use to children as young as 2, pregnancy, and insulin-requiring type 2 diabetes, plus US approval for type 2.798 It is sold in the US, UK and EU; in England and Wales NICE recommends it under its hybrid closed-loop program (TA943).18 As durable hardware it involves a pump plus ongoing reservoir, infusion-set and sensor consumables.18

What's coming. Medtronic is rolling out the Abbott Instinct sensor and Simplera Sync disposable sensor to widen CGM choice and shrink on-body footprint, and has stated it plans to file for an interoperable pump indicated for type 2 diabetes to pair with Instinct in that population.8 Real-world data continue to push toward tighter targets — large analyses show users on the optimal settings (100 mg/dL target, 2-hour active insulin time) reaching ~57% time in tight range (70–140 mg/dL) and, in older adults, >80% time in range without added hypoglycemia, as reported in the cited studies.2324

September access check. MiniMed’s 1 September 2026 update confirms European commercial launch of the 780G with Instinct and MiniMed Go with Instinct Go. Product configurations and eligibility remain region-specific.19

What's next for this

  • →Rollout of Abbott Instinct sensor and Simplera Sync disposable sensor to widen CGM choice
  • →Planned 510(k) filing for an interoperable pump indicated for type 2 diabetes to pair with Instinct

Sources

  1. [1]
    FDA Class II recall Z-2698-2026 — MiniMed 780G software 6.62 OUS with Instinct · Regulatory decision · 2026-07-08 — Open recall initiated 27 May 2026 for 778 pumps distributed in Spain, Great Britain, the Netherlands, and Italy. When paired with Instinct, a software anomaly can trigger Errors 53 and 23 and stop insulin delivery; users were instructed to update from software 6.62 to 6.63.

    U.S. FDA. Class II Device Recall MiniMed 780G Insulin Pump, software version 6.62 OUS — Z-2698-2026 (open and classified; see the FDA record for initiation and posting dates).

  2. [2]
    FDA Class I recall Z-0003-2025 — impact-damaged MiniMed pump battery life · Regulatory decision · 2024-10-03 — Open worldwide correction covering all serial numbers of listed 670G, 770G and 780G models (526,558 pumps). Physical impact can shorten battery life and the warning interval before insulin stops.

    U.S. FDA. Class I Device Recall MiniMed 670G, 770G and 780G pumps — Z-0003-2025 (open; impact damage can shorten battery-warning time; 526,558 pumps worldwide).

  3. [3]
    FDA Class II recall Z-1359-2022 — MiniMed 780G battery-cap contact · Regulatory decision — Open correction for affected outside-US 780G serials. A deteriorated battery-cap contact can interrupt power; inspect/replace affected caps.

    U.S. FDA. Class II Device Recall MiniMed 780G battery-cap contact — Z-1359-2022 (open; affected outside-US serials; inspect/replace cap).

  4. [4]
    FDA Class II recall Z-1238-2026 — MiniMed 780G software 6.60 · Regulatory decision · 2026-02-02 — Open correction for 577 named US/Israel pumps. Errors 41 or 43 can suspend insulin delivery.

    U.S. FDA. Class II Device Recall MiniMed 780G software 6.60 — Z-1238-2026 (open; Errors 41/43 can suspend delivery).

  5. [5]
    FDA Class II recall Z-1635-2026 — MiniMed 780G software delivery defects · Regulatory decision · 2026-03-24 — Open correction covering 26,851 named pumps on software 6.60/6.61 and identified 6.62 defects; errors can cause under-, over-, or no delivery.

    U.S. FDA. Class II Device Recall MiniMed 780G software delivery defects — Z-1635-2026 (open; named 6.60/6.61 pumps and identified 6.62 defects; under-, over-, or no delivery).

  6. [6]
    FDA Class II recall Z-1741-2026 — MiniMed pump position relative to site · Regulatory decision · 2026-04-02 — Open worldwide labeling correction covering 453,144 MiniMed pumps, including all 780G models. Relative height can cause over-/under-delivery; never place the pump over 14 in above the site.

    U.S. FDA. Class II Device Recall MiniMed pump position relative to infusion site — Z-1741-2026 (open; 453,144 pumps worldwide; includes all 780G models).

  7. [7]
    FDA Approves Medtronic MiniMed 780G System — World's First Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections · Manufacturer · 2023-04-21

    Medtronic. FDA Approves Medtronic MiniMed 780G System — World's First Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections (Apr 21, 2023; approved for ages 7+ with type 1 diabetes; SmartGuard auto-corrections every 5 minutes; glucose target as low as 100 mg/dL).

  8. [8]
    FDA Clears MiniMed 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes · Manufacturer · 2025-09-02

    Medtronic. FDA Clears MiniMed 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes (Sep 2, 2025; SmartGuard cleared as an interoperable automated glycemic controller (iAGC); Abbott Instinct sensor up to 15-day wear; type 2 approval for adults 18+; Simplera Sync pre-orders; company-discussed filing for an interoperable type 2 pump).

  9. [9]
    Medtronic secures CE Mark for MiniMed 780G System including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes · Manufacturer · 2025-07-21

    Medtronic. Medtronic secures CE Mark for MiniMed 780G System including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes (Jul 21, 2025; trial data in children aged 2–6; pregnancy indication; European type 2 approval).

  10. [10]
    MiniMed 780G System Support — FAQ (waterproof rating, MiniMed Mobile app, Bolus Wizard) · Manufacturer

    Medtronic (MiniMed). MiniMed 780G System Support — FAQ (waterproof IPX8 to 12 ft / 3.6 m for up to 24 h; MiniMed Mobile app for monitoring/sharing; boluses entered on the pump via the Bolus Wizard).

  11. [11]
    Extended Infusion Set and Extended Reservoir — product overview (up to 7-day wear, use with MiniMed 780G) · Manufacturer

    Medtronic (MiniMed). Extended Infusion Set and Extended Reservoir — product overview (the only infusion set indicated for up to 7 days of wear; use the Extended set and reservoir with the MiniMed 780G system; up to 300 units).

  12. [12]
    Medtronic Secures FDA Clearance For First Ever Infusion Set That Can Be Worn Up To 7 Days By People With Diabetes (H-Cap connector, reduced occlusion risk) · Manufacturer

    Medtronic. Medtronic Secures FDA Clearance For First Ever Infusion Set That Can Be Worn Up To 7 Days By People With Diabetes (H-Cap connector is described as improving insulin physical/chemical stability, increasing infusion-site reliability, and reducing the risk of infusion-set occlusion; other sets are 2–3 days).

  13. [13]
    All About the Medtronic MiniMed 780G Closed-Loop Automated Insulin Pump System · Science journalism

    T1D Exchange. All About the Medtronic MiniMed 780G Closed-Loop Automated Insulin Pump System (tubed durable pump; meal detection with autocorrections; reservoir swap without changing the infusion site).

  14. [14]
  15. [15]
  16. [16]
  17. [17]
  18. [18]
    Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes — NICE technology appraisal guidance TA943 · Regulatory decision · 2023-12-19

    National Institute for Health and Care Excellence. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes — NICE technology appraisal guidance TA943 (recommends hybrid closed-loop systems, including the MiniMed 780G, on the NHS in England and Wales for eligible people with type 1 diabetes).

  19. [19]
    MiniMed September 2026 pipeline and launch update · Manufacturer · 2026-09-01

    MiniMed. September 2026 pipeline and commercial update.

  20. [20]
    MiniMed780G current US product specifications and water instructions · Manufacturer — Waterproof capabilities: rating at manufacture requires correctly fitted reservoir/tubing; remove before swimming or bathing; underwater CGM transmission may stop. Checked17September2026.

    MiniMed780G current US product page, Tech specs — Waterproof capabilities.

  21. [21]

    Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. The Lancet Diabetes & Endocrinology (2022); 10(10):720–731. According to PubMed. https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2822%2900212-1/fulltext (DOI)

  22. [22]

    Edd SN, Castañeda J, Choudhary P, et al. Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. Diabetes, Obesity & Metabolism (2023); 25(11):3212–3222. According to PubMed. https://onlinelibrary.wiley.com/doi/10.1111/dom.15217 (DOI)

  23. [23]

    Castañeda J, Arrieta A, van den Heuvel T, Battelino T, Cohen O. Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System. Diabetes Care (2024); 47(5):790–797. According to PubMed. https://pmc.ncbi.nlm.nih.gov/articles/PMC11043222/ (DOI)

  24. [24]

    Smaniotto V, Heller S, O'Neal D, et al. MiniMed 780G system performance in older users with type 1 diabetes: Real-world evidence and the case for stricter glycaemic targets. Diabetes, Obesity & Metabolism (2025); 27(4):2242–2250. According to PubMed. https://pmc.ncbi.nlm.nih.gov/articles/PMC11885105/ (DOI)